U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07250360) titled 'Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC' on Sept. 28.
Brief Summary: Brief Summary The goal of this clinical trial is to evaluate the effect of postoperative adjuvant chemotherapy (ACT) in patients with stage I non-squamous non-small cell lung cancer (NSCLC) after curative resection.
The main questions it aims to answer are:
Does ACT improve recurrence-free survival (RFS) compared with observation alone?
Does ACT provide disease-free survival (DFS) benefit in this patient population?
Researchers will compare the adjuvant chemotherapy group with the observation group to see if chemotherapy reduce...